Table 1.

Subject characteristics

Variables	Missing	Total (N = 64)	Vildagliptin (N = 40)	Glibenclamide (N = 24)	p
Age (years)	0	62 ± 9	61 ± 9	63 ± 10	0.28
Gender male n (%)	0	43 (67)	26 (65)	17 (71)	0.63
Smoking habit n (%)	3	13 (22)	7 (19)	6 (26)	0.72
CVD history n (%)	2	13 (20)	8 (20)	5 (21)	0.94
Hypertension n (%)	2	43 (67)	25 (63)	18 (75)	0.40
Disease duration (yrs)	0	6.5 (3–10)	7 (4–11)	5 (1–10)	0.30
Plasma glucose (mg/dl)	0	154 ± 34	155 ± 36	150 ± 30	0.67
HBA1C (%)	0	7.7 (7.4–8.1)	7.7 (7.4–7.9)	7.7 (7.5–8.1)	0.57
HBA1C (mmol/mol)	0	61 (57–65)	61 (57–64)	61 (58–65)	0.57
Plasma C-peptide (ng/ml)	8	2.67 (2.16–3.52)	2.66 (2.07–3.48)	2.78 (2.21–4.34)	0.69
BMI (kg/m2)	0	29.0 (26.2–33.9)	29.1 (26.8–32.9)	28.9 (25.4–34.1)	0.94
Serum creatinine (mg/dl)	2	0.8 (0.6–0.9)	0.8 (0.6–0.9)	0.8 (0.6–1.0)	1.0
GFR (CKD-EPI) (ml/min/1.73 m2)	3	96.0 ± 12.7	96.1 ± 11.8	96.0 ± 14.5	0.77
Total cholesterol (mg/dl)	2	166.6 ± 30.3	168.5 ± 31.1	163.2 ± 29.8	0.56
HDL-cholesterol (mg/dl)	2	45 (40–54)	45 (41–51)	45 (37–55)	0.82
Tryglicerides (mg/ml)	2	111 (71–155)	100 (68–140)	117 (78–1182)	0.48
GGT (U/l)	4	20 (16–32)	19 (16–30)	23 (14–36)	0.63
AST (U/l)	4	23 (19–28)	23 (18–27)	23 (19–28)	0.89
ALT (U/l)	4	27 (19–38)	27 (19–38)	28 (20–39)	0.63
Uric acid (mg/dl)	4	5.2 (4.5–6.0)	5.2 (4.5–5.9)	5.2 (4.4–6.3)	0.76
EPC (n/106 events)	0	38.0 (24.2–58.2)	39.0 (24.0–58.2)	37.5 (25.0–59.8)	0.81
Therapies
Anti-hypertensive n (%)	2	43 (67)	25 (64)	18 (75)	0.40
Lipid-lowering n (%)	2	44 (69)	26 (67)	18 (75)	0.33
Antiplatelet n (%)	2	30 (47)	20 (51)	10 (42)	0.40
Metformin (mg/day)	0	2000 (1750–2735)	2000 (2000–2550)	2000 (1700–2400)	0.13

Baseline characteristics of the study subjects expressed as (mean ± SD) or median (IQR) for continuous data and n (%) for categorical data